BURKITT SYMPOSIUM - School of Medicine - Trinity College Dublin

23 - 24 JUNE 2011BURKITTSYMPOSIUMDENIS PARSONS BURKITTIRISH BY BIRTH, TRINITY BY THE GRACE OF GOD— A LIFE CELEBRATED

23 - 24 June 2011BURKITT SYMPOSIUMWELCOMEProfessor Owen P. Smith,Chair of Haematology, Trinity College, DublinDear Friends and Colleagues,I would like to take this opportunity to welcome you to Dublin to celebrate theone hundredth year anniversary of the birth of Denis Parsons Burkitt, one ofthe great physician scientists of the twentieth century who had a tremendousability to turn simple clinical observation into major scientific discovery. We arefortunate, not only to be hosting his centenary at the University of Dublin, TrinityCollege, where he graduated in medicine in 1935, but also as this Symposium ispart of the School of Medicine Tercentenary celebrations.The Symposium will function as an exclusive forum for family and friends ofDenis together with international experts to share and compare experiences inrelation to the lymphoma that is named after him. With this in mind, the first dayof the conference will mainly focus on Denis, the man, physician scientist and hismain legacy, the discovery and early treatment strategies of the commonest cancer in sub-Saharan African children.The second day will focus on recent developments in term of diagnostics, prognostic markers, risk-stratificationmethodologies and clinical trial outcomes. The molecular pathobiology of Burkitt lymphoma will be addressed bysome of the world’s leading experts and true clinical discussion between practicing physicians and researchers onunresolved issues will follow. At the end of the second day participants will have the advantage of discussing anddebating the unresolved issues, especially those most relevant in third world countries.During the Symposium there will be, for the first time, an exhibition of a selection of key artefacts that were pivotal innailing down the association of lymphoma incidence and geography.I hope you find the programme exciting, as I do believe it will provide a meaningful platform providing up-to-dateinformation, not only for basic / translational science researchers but also for clinical haemato-oncologists, nursesand students alike.I look forward to meeting you over the next two days and to celebrate the life of Denis Parsons Burkitt in the beautifulenvirons of Trinity College.Professor Owen P. SmithChair of Haematology, Trinity College Dublin.Page 1

23 - 24 June 2011BURKITT SYMPOSIUM23 - 24 June 2011BURKITT SYMPOSIUMSUPPORTThis Symposium has been made possible by the generous support of:TABLE OF CONTENTSWELCOMESUPPORT & THANK YOUTABLE OF CONTENTSPROGRAMME - Day 1PROGRAMME - Day 2DENIS PARSONS BURKITTGENERAL SYMPOSIUM INFORMATIONFEATURED SPEAKERSNOTES123457101430THANK YOUMrs Olive Burkitt and daughters Judy, Cas and RachelTrinity Foundation OfficeMaurice Ward Group, especially Chris Primrose for the safe delivery ofthe donation of Dr Burkitt’s papers to Trinity CollegePage 2Page 3

23 - 24 June 2011BURKITT SYMPOSIUM: PROGRAMME23 - 24 June 2011BURKITT SYMPOSIUM: PROGRAMMEPROGRAMME DAY 1 THURSDAY, 23 JUNE, 2011 PROGRAMME DAY 2 FRIDAY, 24 JUNE, 201109.00 - 09.30 Registration / Refreshments in the Anatomy BuildingWELCOME AND INTRODUCTION09.30 - 10.00 Professor Owen Smith, Chair of Haematology, University of Dublin, Trinity College, IrelandDr Mary Robinson, Chancellor of the University of Dublin and Former President of Ireland;Prof Dermot Kelleher Vice-Provost of Medical Affairs TCD; Members of Dr Burkitt’s family -Mrs Olive Burkitt, Mrs Cas Boddam Whetham, Mrs Judy Howard10.00 - 12.05 SESSION 1: Historical Perspectives (1)Chair - Professor Owen Smith, University of Dublin, Trinity College, Ireland10.00 - 10.20 Denis Parsons Burkitt — Irish by birth, Trinity by the grace of GodProfessor Owen SmithUniversity of Dublin, Trinity College, Ireland10.20 - 10.45 Nailing Burkitt lymphoma — time with Denis in AfricaProfessor Dennis WrightFormer Histopathologist at Makerere Medical School, Uganda10.45 - 11.10 Burkitt lymphoma and the discovery of the Epstein-Barr virusProfessor Sir Anthony Epstein, CBE, FRSNuffield Department of Medicine, University of Oxford, UK11.10 - 11.45 Into and out of Africa — taking over from Denis BurkittProfessor John ZieglerUniversity of California – San Francisco, USA11.45 - 12.05 Q & A12.05 - 13.00 Lunch13.00 - 14.50 SESSION 2: Historical Perspectives (2)Chair - Professor Owen Smith, Dublin, Ireland13.00 - 13.25 Living and dealing with Burkitt lymphoma in TanzaniaDr Trish ScanlanThe Ocean Road Cancer Institute, Tanzania13.25 - 13.50 Burkitt lymphoma in Uganda: An update on disease statusDr Jackson OremUganda Cancer Institute, Kampala, Uganda13.50 - 14.30 Epidemiological insights into the pathogenesis of endemic and non-endemic Burkitt lymphomaProfessor Ian MagrathInternational Network for Cancer Treatment and Research, Belgium13.30 - 14.50 Q & A14.50 - 16.00 Refreshments and break16.00 - 18.00 Organised tours of Trinity College starting in Anatomy Lecture Theatre08.30 - 9.00 Registration / Refreshments in the Anatomy Building09.00 - 11.20 SESSION 3: Molecular InsightsChair - Professor Finbarr Cotter, London, UK09.00 - 09.40 Is Burkitt lymphoma an infectious disease — a new role for EBV?Professor Georg BornkammInstitute of Clinical Molecular Biology and Tumour Generics, German Research Centre forEnvironmental Health, Germany09.40 - 10.20 New insights into the molecular pathogenesis of Burkitt lymphomaProfessor Riccardo Dalla-FaveraInstitute for Cancer Genetics and H. Irving Comprehensive Cancer Centre, Columbia University,New York, USA10.20 - 11:00 Genomic approaches to molecular diagnosis and molecular targets in Burkitt lymphoma/leukaemiaProfessor Louis StaudtCentre for Cancer Research, National Cancer Institute, Maryland, USA11.00 - 11.20 Q & A11.20 - 11.40 Refreshments11.40 - 13.15 SESSION 4: Therapeutic Strategies (1)Chair - Professor Ian Hann, Cork, Ireland11.40 - 12.20 Staging and response evaluation of Burkitt lymphomaProfessor John SandlundSt Jude Children’s Research Hospital, Tennessee, USA12.20 - 13.00 Therapeutic developments Burkitt lymphoma/leukaemia since 1956Professor Ross PinkertonQueensland Children’s Cancer Centre, Brisbane, Australia13.00 - 13.15 Q & A13.15 - 14.00 Lunch14.00 - 15.40 SESSION 5: Therapeutic Strategies (2)Chair - Dr Elizabeth Vandenberghe, Dublin, Ireland14.00 - 14.40 Prognostic factors and current treatment strategies and outcome results in childrenand adolescents with Burkitt lymphoma/leukemiaProfessor Mitchell S CairoMaria Fareri Children’s Hospital at Westchester Medical Center, New York Medical College, New York, USA14.40 - 15.20 Burkitt lymphoma in adultsProfessor David LinchUniversity College London, UK15.20 - 15.40 Q & A15.40 - 16.00 Refreshments18.00 - 19.30 Wine reception and Burkitt exhibition - The Old LibraryPage 4Page 5

23 - 24 June 2011BURKITT SYMPOSIUM: PROGRAMME16.00 - 18.15 SESSION 6: Therapeutic Strategies & BeyondChair - Professor Ian Magrath, Brussels, Belgium16.00 - 16.40 Vaccine therapy for lymphomas — are we there yet?Associate Professor Stephen SchusterUniversity of Pennsylvania Medical School, USA16.40 - 17.10 Infection and cancer: the legacy of BurkittDr Joe HarfordDirector of the Office of International Affairs, National Cancer Institute, Bethesda, MD, USA17.10 - 17.50 Burkitt lymphoma — is it possible to cure more with less?Round table discussion with Professor Ian Magrath, Professor John Ziegler,Dr Joe Harford and Professor Owen P Smith17.50 - 18:05 Closing remarks and farewellProfessor Owen P SmithDENIS PARSONS BURKITT1911 - 1993IRISH BY BIRTH, TRINITY BY THE GRACE OF GOD — A LIFE CELEBRATEDA GREAT TWENTIETH-CENTURY IRISH DOCTORPage 6Page 9

23 - 24 June 2011BURKITT SYMPOSIUM23 - 24 June 2011BURKITT SYMPOSIUMBURKITT A GREAT TWENTIETH-CENTURY IRISH DOCTORBorn near Enniskillen in County Fermanagh, Ireland on 28 February, 1911, Denis himself admitted not being a stellarstudent. In 1929 he applied to Trinity College Dublin to study his father’s profession, engineering, despite a tutorwriting to his father expressing doubts if Burkitt would be capable of earning a degree. During his first year at Trinityhe joined Room 40, a small group of undergraduates who met regularly for prayer and Bible study, and committed hislife to Jesus Christ. His religious convictions would be a driving force for the rest of his life. Soon after his commitmentto Christianity, he felt that God was calling him to devote his life to medicine. He changed his study to medicine andgraduated with his MB on 5 July, 1935. After graduating from Trinity College Dublin he continued his surgical trainingand obtained Fellowship of the Royal College of Surgeons in Edinburgh in 1938. He went on to write his MD entitled‘Spontaneous rupture of abdominal viscera’ in 1947.While serving as a ship’s surgeon in 1938, Burkitt decided he would be a surgeon first and a missionary second andhoped to work with the Colonial Service in West Africa. During his five year sojourn as an army surgeon during WorldWar Two, he married Olive Mary Rogers, a trainee nurse he had met while working as the Resident Surgical Officer atthe Prince of Wales Hospital in Plymouth.Despite having his application to the Colonial Office being turned down on account of his loss of sight in one eye,Burkitt passed a medical and enlisted into the Royal Army Medical Corps. He was posted to a military hospital inMombasa. During his 18 months as an army surgeon he travelled a great deal in East Africa learning Swahili in theprocess. Towards the end of the war he applied again to the Colonial Office requesting work as a medical officer inUganda. This time his application was accepted.In 1957 Burkitt was asked to examine a five year old boy in the paediatric ward who exhibited tumours in his neckand head. A few weeks he saw another child with the same pattern of malignant jaw tumours. The tumours wereextremely fast growing and those affected died within weeks. Believing he was witness to a previously undescribedcancer he began to contact a number of hospitals in Africa.In 1961 along with colleagues Edward Williams and Clifford Nelson, Burkitt undertook a 16,000km research travelvisiting at least 56 hospitals in East and Southern Africa. Their mission was to study the occurrence and distributionof lymphomas. Much to their delight, they visited some of the places Livingstone had worked a century before them.With meticulous data collection along the way they soon realised that the lymphoma was correlated with the sametemperature and rainfall zones as malaria leading them to initially believe that the lymphoma may have been linkedwith the distribution of certain insect carriers as malaria. Always one to conduct his research in the most frugal ofmanners, the entire expedition cost £678.00 according to Burkitt’s biographer Brian Kellock.children of their tumours, he was doing it with drug doses so low that they caused none of the expected side effects.Expert pathologists from around the globe soon acknowledged that this was a newly described disease and coinedthe name ‘Burkitt lymphoma’ to describe this particular type of tumour. The enormity of Burkitt’s contribution can beassessed from the statistic that Burkitt lymphoma accounts for over half of the childhood cancers in Africa.Denis Burkitt is one of the few medical doctors who won world acclaim for two medical discoveries. The first, assummarised above, was to uncover the causes and pioneer a cure for the cancer known now as Burkitt lymphoma. Thesecond was to confirm the link between many Western diseases and the lack of fibre in the Western diet.It was naval surgeon Captain T. L. Cleave who first introduced Burkitt to his theory that refined carbohydrates was thesource of many chronic diseases in the Western world. After meticulously researching the world wide geographicaldistribution of bowel cancer, he hypothesised that the deficiency of fibre in the Western diet was the major factorresponsible for the high prevalence of this disease in affluent societies. Although at first not considered to be notable,his publications on the role of fibre in the diet increasingly became cited over the next ten years. By 1980 his workswere considered ‘citation classics’ on the subject of bowel cancer. As his publications on Burkitt lymphoma by thistime were also considered ‘citation classics’ it is worth mentioning that not many men have achieved this distinctionin two entirely unrelated fields of medical research.Burkitt was the recipient of many prestigious international awards throughout his career. In 1982 he received theBristol-Myers Award jointly with Tony Epstein for the work they had done in discovering and establishing the importanceof the virus that became known as the Epstein-Barr Virus. That same year Burkitt received the Mott General MotorsAward. Denis Burkitt was also made an honorary Fellow of Trinity College, its highest award, for service in medicineand surgery. Denis Burkitt died on 23 March, 1993. His contributions relieved the world of much misery by directlyproviding a cure for Burkitt lymphoma and indirectly by preventing disease through his high-fibre diet. It has beennoted that throughout his life he remained modest and humble. When asked to autograph a book, he used to write:‘Attitudes are more important than abilitiesMotives are more important than methodsCharacter is more important than clevernessAnd the heart takes precedence over the head.’Burkitt’s first published his research in The British Journal of Surgery in 1958. The publication went unnoticed. It washis article, co-written with Greg O’Conor, entitled ‘Malignant tumours in African children: A clinical syndrome’ andpublished in Cancer in 1961 that would make a mark in the medical world.While attending a UK lecture, Burkitt met young virologist Doctor, now Sir Tony Epstein. Burkitt sent Epstein sometumour samples and after three years of searching, Epstein’s team demonstrated a virus in the tumour cells. TheEpstein-Barr virus was the first to be shown to be oncogenic in humans. Following this it was noted that the ‘lymphomabelt’ mapped by Burkitt in Africa corresponded to the areas where mosquitoes thrived, i.e., low level high heat andwater and where malaria was endemic. The malaria caused the suppression of childhood immune systems and thisallowed the Epstein-Barr virus to stimulate lymphoid cells to undergo malignant transformation.Using creative thinking, Burkitt convinced the pharmaceutical companies to supply chemotherapeutic agents. Hislogic was that due to the lack of radiotherapy equipment and that none of his patients had been exposed to x-rays,and relying solely on medication, the drug companies could assess what effect their drugs were truly having onpatients. In giving Burkitt their drugs free of charge, he would use them and report on their efficacy. As Burkitt noted,“Chemotherapy agents were obtained free of charge from the manufacturers who were approached in an attitude ofbegging, clothed in the appearance of offering opportunities. In western countries it was difficult to assess the effect ofchemotherapy because in most patients, radiotherapy had also been used.” Since monitoring patients was so difficulthe thought it unwise to work close to the toxic limits of the drugs, Burkitt discovered that not only was he curing thePhoto Credit: http://understandingscience.ucc.ie/pages/sci_denisburkitt.htmOn a personal note, family was always of major importance in Denis Burkitt’s life and we are pleased and honouredto welcome to the Symposium his wife Olive Burkitt and two of Denis’ daughters, Judy Howard and Cas BoddamWhetham. His daughter Rachel was unable to attend but sends her regards.Referenceshttp://understandingscience.ucc.ie/pages/sci_denisburkitt.htmhttp://www.whonamedit.com/doctor.cfm/2199.html1985 Kellock, Brian. The Fibre Man. The Life story of Dr Denis Burkitt. Tring: Lion Publishing plc.Page 8Page 9

23 - 24 June 2011BURKITT SYMPOSIUM: GENERAL SYMPOSIUM INFORMATION23 - 24 June 2011BURKITT SYMPOSIUM: GENERAL SYMPOSIUM INFORMATIONGENERALSYMPOSIUMINFORMATIONAll information about theconference will be regularlyupdated on the website:http://www.medicine.tcd.ie/tercentenary/news-events/burkittsymposium.php.Please check thesite regularly for updates.The Symposium officially beings at09:30 on Thursday, 23 June, 2011with a Welcome by the former IrishPresident and the Chancellor ofthe University of Dublin Dr MaryRobinson, Professor DermotKelleher, Vice-Provost of MedicalAffairs and Head of School ofMedicine, Professor Owen Smith,Chair of Haematology TrinityCollege Dublin, and members ofDr Burkitt’s family namely DenisBurkitt’s wife Mrs Olive Burkittand daughters Mrs Cas DoddamWhetham and Mrs Judy Howardin the Anatomy Building LectureTheatre.COMPLETIONOF REGISTRATIONSYMPOSIUMLOCATIONAll registration fees and any othercharges must be paid in full inorder to complete your registrationprior to your arrival.The Symposium will be held in theAnatomy Building Lecture Theatre.There are three main access pointsthat can be used. The main gateto the college on College Green orthe entrance from Nassau Street/Dawson Street will bring youon campus where you can walkthrough campus, past College Parkto the Anatomy Building.Access can also be gained viathe Lincoln Place gate and fromthere it is a short walk around theChemistry Building to the AnatomyBuilding.TRAVELTO DUBLINPlease make your own travelarrangements to Dublin.If arriving by air, transportationfrom the airport to Dublin’s citycentre is best done by Aircoach,a bus service to and from bothterminals at Dublin Airport. TheAircoach makes a stop at TrinityCollege, very close to the frontgates, and within easy walkingdistance of several hotels. Roundtrip cost is approximately 12 euros.The return Aircoach to the airportleaves from Dawson Street orSuffolk Street every ten minuteswhich is very close to TrinityCollege. For more informationabout this service see http://www.aircoach.ie/aircoach.journey.wizard.php.Allow 30-60 minutes to get to/fromthe airport/city centre via Aircoach.For those wishing to take a taxi,there is a taxi rank outside themain gates of Trinity College.ACCOMMODATIONPlease make your ownaccommodation arrangements.There are numerous hotels in thecity centre. We have contacted afew for special rates and they arenoted on our website at: http://www.medicine.tcd.ie/tercentenary/news-events/burkitt-symposium.php#accommodation. Pleasenote that a few hotels only offerthe rates if booked prior to noteddates.CONFERENCERECEPTION DESKThe Conference Reception Deskwill be located in the AnatomyBuilding. Upon arriving pleaseregister. You will receive yourSymposium Programme as wellas a Symposium badge at thattime. Please wear your badge atall times during the Symposiumas only delegates with officialSymposium ID will be allowed intoany of the sessions and functions.Page 10Page 11

23 - 24 June 2011BURKITT SYMPOSIUM: GENERAL SYMPOSIUM INFORMATION23 - 24 June 2011BURKITT SYMPOSIUM: GENERAL SYMPOSIUM INFORMATIONSESSIONS &PAPERSSessionsAll sessions take place in theAnatomy Building Lecture Theatre.The programme details sessionlengths with ample time forquestions at the end of the sessionas well as breaks.PapersFull papers are only availabledirectly from the authors at theirdiscretion. Email addresses of alldelegates are available at the endof this Symposium Programme.The proceedings of the Symposiumare intended to be published inthe form of a Themed Issue for theBritish Journal of Haematology.We will advise all participants indue course when the issue will bereleased.CATERING & DINNERSRefreshments will be servedbefore the Symposium eachmorning as well as at the breaks,as indicated in the SymposiumProgramme. Lunch will be servedon both days. All those attendingthe Symposium who are notfeatured speakers are free to maketheir own dinner plans for eachday of the conference. There arenumerous restaurants to choosefrom in the city centre off campusjust beyond the Nassau Street/Dawson Street and College Greenentrances.If you have any special dietaryrequirements, please ensure theyare noted when registering forthe Symposium via our onlineregistration system or pleaseinform leslie.mccartney@tcd.ie assoon as possible.PHOTOCOPYING,INTERNET ACCESS,DRESS CODE &CAR PARKINGPhotocopyingThere are no photocopyingfacilities available to use but thereare a few retail outlets on NassauStreet which can provide you withthis service, for example Readslocated in the Setanta Centre onNassau Street (http://www.reads.ie/photocopying.html)Internet AccessWe regret that access to the TrinityWiFi system is not available toguests. There are however manyWiFi hotspots in the city centre aswell as internet cafés.A listing of various Dublin internetcafé locations can be found athttp://www.dublinuncovered.net/cyber.htmlDress CodeThe dress code for the entireSymposium including the receptionis smart casual.Car ParkingThere are several public car parksclose to Trinity College.TOURISTINFORMATION &POST OFFICEA tourism information centreis located very close to TrinityCollege. It is housed in a renovatedchurch and is located on SuffolkStreet, just west of GraftonStreet, across the street fromO’Neill’s pub. You can also viewtourist information at http://www.visitdublin.com/. A Post Officeis located just down St AndrewStreet, west of the tourist centre.SOCIAL EVENTSWe are arranging historicalwalking tours of campus on theafternoon of Thursday 23 June,2011 beginning at 16:00. Pleasewear comfortable shoes andbring an umbrella. You usually donot need to worry about wearingsunscreen in Dublin. More detailsabout the tour will be available onthe day.invited to a wine reception, anopportunity to view an exhibitionfeaturing some of Dr Burkitt’smemorabilia in the Long Room.The tour ends at 18:00 at the OldLibrary where participants arePage 12Page 13

23 - 24 June 2011BURKITT SYMPOSIUM: FEATURED SPEAKERS23 - 24 June 2011BURKITT SYMPOSIUM: FEATURED SPEAKERSProfessor GEORG W BORNKAMMInstitute of Clinical Molecular Biology and Tumor Generics,German Research Centre for Enviromental Health, Germany24 June 201109:00 - 09:40Professor MITCHELL S CAIROMaria Fareri Children’s Hospital at Westchester Medical Center,New York Medical College, USA24 June 201114:00 - 14:40Georg W Bornkamm received his degree at the Medical School of the Ludwig-Maximilians-Universität in Munich in1970 with a thesis in Biochemistry on histones and chromatin. In 1972 he joined the lab of Nobel Laureate (2008) Haraldzur Hausen in the Department of Clinical Virology of the University of Erlangen as a post-doctoral fellow and started towork on the genomic structure of oncogenic herpes viruses. In 1975 he worked with Tomas Lindahl and Alice Adamsin the Department of Biochemistry and Microbiology, Tumor and Cell Biology at the Karolinska Institute in Stockholmon the episomal nature of the Epstein-Barr virus (EBV) genome in Burkitt lymphoma and Nasopharyngeal Carcinoma.Back at the University of Erlangen he became Lecturer of Virology in 1976 (Habilitation). In 1978, he was appointed asa Professor of Virology in the Institute of Microbiology and Hygiene at the University of Freiburg (Germany).In the early eighties, comparing the genomic structure of transforming and non-transforming EBV strains he identifiedthe region in the viral genome that maps for EBV´s oncogene and transcriptional master regulator EBNA2. He alsoparticipated in the large prospective study on the role of EBV in Burkitt lymphoma in Uganda that had been organizedand guided by Guy de Thé at the International Agency for Research on Cancer (IARC) in Lyon. From 1983 to 1989 he wasSpeaker and Coordinator of the Research Initiative (Sonderforschungsbereich) “Tumor Development” of the GermanResearch Foundation (DFG) at the University of Freiburg. From 1989 to 2008 he has been Director of the Institute ofClinical Molecular Biology and Tumor Genetics in the Helmholtz Center Munich. In 1993/1994 he spent a sabbatical atthe German Cancer Center at Heidelberg.In the nineties Dr Bornkamm’s laboratory contributed significantly to our understanding of EBNA2’s mode of actionas a transcription factor and developed conditional EBV-immortalized cells with reconstructed breakpoints ofchromosomal translocations of Burkitt lymphoma cells and with a Tetracycline-regulatable c-Myc gene that mimicessential features of Burkitt lymphoma cells and have become important tools to study the interplay between viraland cellular oncogenes. The analysis of c-Myc’s immunomodulatory function in B cell lymphoma cells led him intothe field of tumor immunology and initiated his present research on the generation of high-affinity T cells againstB-cell specific differentiation antigens. He received several awards including the Gottfried-Wilhelm-Leibniz Prize ofthe German Research Foundation. Since 2008 he is running a small group as an emeritus professor at the HelmholtzCenter Munich.RECENT REVIEWS:Mitchell S. Cairo received his M.D. from UC San Francisco, trained in pediatrics at UCLA/Harbor General Hospital, wasChief Resident in pediatrics at UCSF, and completed a fellowship in pediatric hematology/oncology at Indiana University.He joined the hematology/oncology faculty of Children’s Hospital of Orange County (CHOC) in 1982 and established theBMT/Stem Cell Transplant program there in 1985. He was also the CHOC Principal Investigator for Children’s CancerGroup, and the Principal Investigator of the Cord Blood Collection Center and Cord Blood Transplant Center under anNHLBI award. From December 1997 to February 2000, Dr Cairo was a member of the faculty at Georgetown Universitywhere he was a Professor of Pediatrics, Medicine and Pathology, Chief of Pediatric Hematology/Oncology, Cellular andGene Therapy, Director of Adult and Pediatric Blood and Marrow Transplantation at the Lombardi Cancer Center, andMedical Director of the NHLBI Cord Blood Collection Center at Georgetown University Medical Center. He relocatedto Columbia University in New York City in March 2000, where he was the Chief of the Division of Pediatric Blood andMarrow Transplantation, a Professor of Pediatrics, Medicine and Pathology at Columbia University and director of thePhase I Pediatric Cancer Therapeutics Program and Pediatric Hematology-Oncology Fellowship Training Program,the Chief of Pediatric Hematology, Oncology and Stem Cell Transplantation. More recently, Dr Cairo has relocatedin February, 2011 to the New York Medical College where he is the Chief of Pediatric Hematology, Oncology andStem Cell Transplantation, Director of the Childhood and Adolescent Cancer and Blood Disease Center, Medical andScientific Director of the Stem and Cellular Therapy Reengineering Laboratory and Professor of Pediatrics, Medicine,Pathology, Microbiology and Immunology and Cell Biology. Dr Cairo has over 275 peer reviewed publications and over850 national and international presentations. He is an international leader in childhood lymphomas and leukemias,stem cell transplantation, pediatric cancer developmental therapeutics, unrelated donor stem cell transplantation andexperimental hematopoiesis. His major research interests and expertise include blood and marrow transplantation,experimental and developmental immunology, molecular genetics of lymphoma, developmental therapeutics andclinical leukemia and lymphoma investigation.Dr Cairo has focused a major part of his research in Burkitt Lymphoma. Dr Caro has led the CCG/COG Burkitt lymphomastudies for the past 20 years. He was one of the three Co-Chairs and the CCG Chair of the French-American-British(FAB) Burkitt lymphoma study that resulted in a significant reduction in both chemotherapy and radiotherapy and animprovement in survival in this patient population. Dr Cairo has also focused on novel immunological approaches bothantibodies and cellular based therapies for Burkitt lymphoma. Lastly, Dr Cairo’s laboratory has identified a number ofspecific genetic defects in Burkitt lymphoma and has developed targeted approaches to these genetic defects.Bornkamm, W.W. (2009a). Epstein-Barr virus and its role in the pathogenesis of Burkitt lymphoma: an unresolvedissue. Semin Cancer Biol 19, 351-365.Bornkamm, W.W. (2009a). Epstein-Barr virus and the pathogenesis of Burkitt lymphoma: more questions thananswers. Int J Cancer 124, 1745-1755.Page 14Page 15

23 - 24 June 2011BURKITT SYMPOSIUM: FEATURED SPEAKERS23 - 24 June 2011BURKITT SYMPOSIUM: FEATURED SPEAKERSProfessor RICCARDO DALLA-FAVERA M.D.Professor of Pathology and Genetics and Development,Institute for Cancer Genetics and H. Irving Comprehensive CancerCenter, Columbia University, New York, New York, USA24 June 201109:40 - 10:209. Compagno, M., Lim, W.K., Grunn, A., Nandula, S.V., Brahmachary, M., Shen, Q., Bertoni, F., Ponzoni, M.,Scandurra, M., Califano, A., Bhagat, G., Chadburn, A., Dalla-Favera, R. and Pasqualucci, L. Mutations of multiplegenes cause deregulation of the NF-kB pathway in diffuse large B-cell lymphoma. Nature 459:717-21, 2009.10. Pasqualucci, L., Dominguez-Sola, D., Chiarenza, A., Fabbri, G., Grunn, A., Trifonov, V., Kasper, L.H., Lerach, S.,Ma, J., Rossi, D., Mullighan, C., Rabadan, R., Gaidano, G., Brindle, P.K., Dalla-Favera, R. Inactivating mutations ofacetyltransferase genes in B-cell lymphoma. Nature, in press.Riccardo Dalla-Favera, M.D. holds the Joanne and Percy Uris Chair of Clinical Medicine, he is Professor of Pathology,and Professor of Genetics & Development at the College of Physicians & Surgeons of Columbia University. He is alsothe Director of the Institute for Cancer Genetics, and the Director of the Herbert Irving Comprehensive Cancer Centerat Columbia University. He is the Director of the Specialized Center for Research on Lymphoma at Columbia University.He is the author of 200 publications and the co-editor of the textbook “Non Hodgkin Lymphoma” (Lippincott, Williams& Wilkins publishers).Dr Dalla-Favera has been recognized with several national awards, including the Stohlman Award from The LeukemiaSociety of America, two NIH MERIT Awards (1989, 2005), and the 2006 William Dameshek Prize for OutstandingContribution to Hematology from The American Society of Hematology. In 2011 he has been elected to the Institute ofMedicine of the National Academy of Sciences, USA.Dr Dalla-Favera has been an active researcher in the field of lymphoma research for more than 30 years. His careerstarted with his pioneering work on the cloning and chromosomal mapping of human proto-oncogenes, includingc-Myc (1-2). This work established the basis for the seminal work on the involvement of c-Myc in chromosomaltranslocations in Burkitt lymphoma (3-5). Then, his research has continued to yield new insights into the pathogenesisof human B cell lymphomas, and, in particular, on the identification of the genetic lesions and biological mechanismsresponsible for the development of these diseases (6-10).1. Dalla-Favera, R., Gelmann, E.P., Martinotti, S., Franchini, G., Papas, T.S., Gallo, R.C., and Wong-Staal, F. Cloningand characterization of different human sequences related to the onc-gene (v-myc) of avian myelocytomatosisvirus (MC29). Proc. Nat. Acad. Sci. USA 79:6497-6501, 1982.2. Dalla-Favera, R., Bregni, M., Erikson, J., Patterson, D., Gallo, R.C., and Croce, C.M. The human c-Myc onc-geneis located on the region of chromosome 8 which is translocated in Burkitt lymphoma cells.Proc. Nat. Acad. Sci. USA 79:7824-7827, 1982.3. Dalla-Favera, R., Martinotti, S., Gallo, R.C., Erikson, J., and Croce, C.M. Translocation and rearrangements of thec-Myc oncogene locus in human undifferentiated B-cell lymphomas. Science 219:963-967, 1983.Sir ANTHONY EPSTEIN MA, MD, DSc PhD, FRCPath, CBE FRSNuffield Department of Clinical Medicine,University of Oxford, John Radcliffe Hospital, Oxford, UK23 June 201110:45 - 11:10Sir Anthony Epstein was born in London 18 May 1921. He was educated at St Paul’s School, London; Trinity College,Cambridge; and Middlesex Hospital Medical School, London. His numerous qualifications include: MA MD (Cantab);DSc PhD (London); FRCPath. He has held the following appointments: Assistant Pathologist, Middlesex Hospital:Reader & Hon Consultant Virologist, Middlesex Hospital Medical School; Professor of Pathology & Head of Department,University of Bristol; Emeritus Professor at Nuffield Department of Clinical Medicine, University of Oxford & HonoraryFellow of Wolfson College.Sir Anthony Epstein has been the recipient of a number of honours including numerous medals, honorary degrees,honorary professorships and fellowships, named and leading lecturerships and holds four international prizes. Hewas elected to the Royal Society in 1979, served on Council, as Foreign Secretary and as Vice President; was appointedCommander of the Order of the British Empire 1985 and Knighted in 1991.He has served on numerous scientific advisory committees and research boards; on Executive Council, EuropeanScience Foundation; on Executive Board, International Council of Scientific Unions; as Special Representative of theDirector General of UNESCO; on Advisory Group, World Bank China Key Development Project.He is the author of 252 original contributions in leading international scientific journals and 5 books. He is the jointfounder and Editor of the International Review of Experimental Pathology vols 1-26.4. Identification of reciprocal translocation points within the c-Myc and immunoglobulin m loci in a Burkittlymphoma. Nature 306:799-803, 1983.5. Lombardi, L., Newcomb, E.W., and Dalla-Favera, R. Pathogenesis of Burkitt lymphoma: Expression of anactivated c-Myc oncogene causes the tumorigenic conversion of EBV-infected human B-lymphoblasts.Cell 49:161-170, 1987.6. Ye, B.H., Lista, F., LoCoco, F., Knowles, D.M., Offit, K., Chaganti, R.S.K., Dalla-Favera, R. Alterations of aZinc-Finger Encoding Gene, BCL-6, in Diffuse Large-Cell Lymphoma. Science 262:747-750, 1993.7. Dominguez-Sola, D., Ying, C.Y., Grandori, C., Ruggiero, L., Chen, B., Galloway, D.A., Gu, W., Gautier, J., Dalla-Favera. R. Non-transcriptional control of DNA replication by c-Myc. Nature 448(7152):445-51, 2007.8. Pasqualucci, L., Bhagat, G., Jankovic, M., Compagno, M., Smith, P., Morse III, HC., Nussenzweig, MC., Dalla-Favera, R. AID is required for germinal center derived lymphomagenesis. Nature Genetics 40(1):108-12, 2008.Page 16Page 17

23 - 24 June 2011BURKITT SYMPOSIUM: FEATURED SPEAKERS23 - 24 June 2011BURKITT SYMPOSIUM: FEATURED SPEAKERSDr JOE B. HARFORDDirector, Office of International AffairsNational Cancer Institute, National Institutes of HealthBethesda, MD 20892, USA24 June 201116:40 - 17:1017:10 - 17:50Professor David Linch FRCP, FRCPath, FMedSciProfessor of Haematology and Head of the Department ofHaematology, University College London (UCL)24 June 201114:40 - 15:20Dr Joe Harford received a Ph.D. in Biochemistry from the University of Maryland Medical School and conducted basicresearch in molecular biology and cell biology. Dr Harford has published over 120 scientific papers. Dr Harford is oneof the founding editors for Current Protocols in Cell Biology.In 1993, Dr Harford became the chief scientist for RiboGene, Inc. (now Questcor Pharmaceuticals, Inc.), a biotechnologycompany where he managed four drug discovery programs in infectious diseases. From 1996 to 1999, Dr Harfordserved as Chairman of the Scientific Advisory Board of RiboGene, Inc, and served in a similar capacity for SynerGeneTherapeutics, Inc., an early-stage biopharmaceutical company that focuses on molecular therapeutics for cancer. DrHarford is a co-inventor on two issued U.S. patents related to drug discovery. In 1996, Dr Harford returned to the NIHwhere he served as Associate Director of the NCI and Chief of Staff of the Office of the Director.In July 2002, Dr Joe Harford was named Director of the Office of International Affairs of the National Cancer Institute. Inthis capacity, he has responsibility for a number of bilateral and multilateral interactions between the NCI and foreigncancer research institutions and other foreign entities. Dr Harford serves as the Chair of the Strategic Advisory Groupof the Ireland-Northern Ireland-NCI Cancer Consortium and as NCI liaison to the Middle East Cancer Consortium, theUS-Japan Co-operative Cancer Research Program, the African Organization for Research and Training in Cancer, theAmerican-Russian Cancer Alliance, and the International Network for Cancer Treatment and Research. Dr Harfordhas represented the United States to the Governing Council of the WHO’s International Agency for Research on Cancerand represented NIH for two years as a member of the Board of Trustees of the Human Frontier Science Program, aninternational non-governmental, nonprofit association devoted to the promotion of basic research. In July 2006, DrHarford was named as Strategic Leader for Knowledge Transfer by the Union for International Cancer Control (UICC).In 2008, UICC altered its committee structure, and Dr Harford was named to the UICC Board of Directors (NCI Liaison),the Solidarity Fund Taskforce, the Childhood Cancer Taskforce, and the Strategic Coordinating Committee. Dr Harfordhas been appointed by the Irish Minister for Health and Children to the National Expert Group on Cancer Biobanking.Dr Harford also serves on the Executive Committee of the Breast Health Global Initiative that strives to develop,implement and study evidence-based, economically feasible, and culturally appropriate Guidelines for InternationalBreast Health and Cancer Control for low and middle-income countries to improve breast health outcomes and accessto breast cancer screening, detection and treatment for women.David Linch is Professor of Haematology and Head of the Department of Haematology at University College London(UCL). He qualified in Medicine from Cambridge University and the Middlesex Hospital Medical School in 1975, andthen undertook SHO and Registrar positions in General Medicine before entering Haematology. He commenced hisresearch career at UCL as a Wellcome Trust Clinical Research Fellow and then an MRC Travelling Research Fellow tothe Dana Faber Cancer Institute in Boston. In 1984 he was appointed a Senior Lecturer at the Middlesex Hospital andfollowing the first of several London Medical School mergers he was appointed to a Chair of Haematology at UCL in1988. He took up the Headship of the Department of Haematology in 1992 and from 2004 to 2007 was the Chairman ofthe Division of Cancer Medicine at UCL. He is currently the Chairman of the CRUK Cancer Centre at UCL.His laboratory research has been in the field of myelopoiesis and myeloid leukaemias and his clinical research hasbeen focussed on the treatment of leukaemia and lymphoma with a particular focus on the development of high dosetherapy strategies. He was the Goulstonian Lecturer of the Royal College of Physicians in 1988 and the recipient of theBritish Society of Haematology Gold Medal in 2006. Professor Linch was the Director of the British National LymphomaInvestigation, Chairman of the UK Lymphoma Group and then the first Chairman of the NCRI Lymphoma ClinicalStudies Group. He has published numerous papers on the treatment of lymphoma in adults. He is the President ofthe Lymphoma Association, a national patient advisory and support organisation. He is the Chairman of the MedicalResearch Council Leukaemia Trials Steering Committee.Professor Linch has served on numerous advisory bodies including the Medical Advisory Panel, the Cell and MolecularPanel and the International Panel of the Wellcome Trust, the Scientific Committee and the Clinical Trials Committeeof Leukaemia and Lymphoma Research (formerly the Leukaemia Research Fund). He currently chairs the LLR CareerDevelopment Panel. He is the immediate past President of the British Society of Haematology.In 2007, Dr Harford was recognized by the Arab Medical Association Against Cancer with an award, the citation ofwhich reads “In recognition for his significant contribution to enhance the status of cancer care and cancer researchin the region and for his unwavering efforts to support needed infrastructure and create opportunities in cancereducation, training and capacity building to help cancer patients and their families throughout the Arab world.”Page 18Page 19

23 - 24 June 2011BURKITT SYMPOSIUM: FEATURED SPEAKERS23 - 24 June 2011BURKITT SYMPOSIUM: FEATURED SPEAKERSProfessor IAN T. MAGRATH DScMed, FRCP, FRCPathInternational Network for Cancer Treatment and Research,Brussels, Belgium23 June 201113:50 - 14:3024 June 201116:00 - 18:1517:00 - 17:50Dr JACKSON OREM MB, ChB, M.MedDirector, Uganda Cancer Institute, Lecturer MakerereUniversity School of Medicine, Kampala, Uganda23 June 201113:25 - 13:50Ian Magrath received his qualifications in medicine from the University of London. He holds a higher doctoral degreein Medicine and is a Fellow of the Royal College of Physicians and the Royal College of Pathologists. He has a specialinterest in the pathogenesis and treatment of non-Hodgkin’s lymphomas, stemming from early in his career whenhe spent 2 years as Director of the Lymphoma Treatment Center in Kampala (University of Makerere), Uganda. Hesubsequently joined the National Cancer Institute (NCI), Bethesda, Maryland, and became Chief of the LymphomaBiology Section of the Pediatric Oncology Branch, where his work was focused on the treatment and molecularpathogenesis of B cell lymphomas, particularly Burkitt lymphoma, as well as the role of Epstein-Barr virus in thepathogenesis of the latter disease. During the last 35 years, he has had a particular interest in cancer control indeveloping countries and has been involved in the conduct of cancer control projects, clinical trials and basic researchin many parts of the world, including India, Pakistan, Nepal, China, Mexico, Argentina, Brazil, Turkey, Tanzania, Kenya,Nigeria and Egypt. This led to his present position as President of the International Network for Cancer Treatment andResearch (INCTR) in Brussels (in 2000), although he retains a position at the NCI. Dr Magrath is also adjunct Professorof Pediatrics at the Uniformed Services University of the Health Sciences in Bethesda, Maryland. He has authoredover 360 original articles, chapters, reviews, commentaries and editorials relating primarily to the pathogenesis andtreatment of malignant lymphomas, pediatric cancers, cancer in developing countries and Epstein Barr Virus. Hehas also edited several books, including “New Directions in Cancer Treatment,” “The Non-Hodgkin’s Lymphomas”(now in its 3rd edition as “the Lymphoid Neoplasms”), and “Gene Therapy.” He serves or has served on severalinternational committees and advisory boards for a number of organizations, including the World Health Organization,the International Atomic Energy Agency (PACT), the European School of Oncology, the International Union for CancerControl and the American Association for Cancer Research. He has won a number of awards for his work and beeninvited to give several special lectures at major meetings of professional societies or Universities.1. Magrath, Ian (Ed). The Lymphoid Neoplasms. Third Edition. Arnold Hodder, London, 2010.2. Magrath I. Lessons from clinical trials in African Burkitt lymphoma. Current Opinion in Oncology, 2009, 21:462–468.3. Gascoyne RD, Magrath IT and Sehn L. Burkitt lymphoma. In Armitage J, Mauch PM, Harris NL, Coiffier B, Dalla-Favera R. Non-Hodgkin lymphomas. Kluwer W. Philadelphia, pp 334-357, 2009.4. Magrath I. B-cell Lymphoma/Burkitt lymphoma. In Pediatric Lymphomas. Weinstein H and Link M (Eds). 2006,141-174. Springer-Verlag, Berlin, Heidelberg.Dr Orem served as a Fogarty Clinical Research Scholar in the Division of Hematology/Oncology (September 2002to January 2004). Dr Orem specialized in clinical oncology at the Division of Hematology/Oncology and Case CancerCenter in line with research activities of the Developmental Therapeutics Program. He is currently involved in thedelivery of cancer care in resource-poor settings as well as the treatment of viral-associated malignancies includingBurkitt lymphoma and the care of patients with compromised immune functions.His honours include: Recipient German Academic Exchange Scholarship (1993-1996); Recipient Fogarty FoundationFellowship (2002-2004); Elected first Chair of International Burkitt lymphoma Task Force (2008); Invited speakerGreater Seattle Chamber of Commerce Conference (2008); Invited education faculty American Society for ClinicalOncology (2008); Annual Conference (2009); Invited speaker 42 International Society of Pediatric Oncology October2010, Boston Massachusetts.SELECTED PUBLICATIONS:Gender differences in clinical presentation and outcomes of epidemic Kaposi sarcoma in Uganda. Phipps W,Ssewankambo F, Nguyen H, Saracino M, Wald A, Corey L, Orem J, Kambugu A, Casper C. PLoS One. 2010 Nov12;5(11):e13936.Ocular surface squamous neoplasia in patients with HIV infection in sub-Saharan Africa.Nagaiah G, Stotler C, Orem J, Mwanda WO, Remick SC. Curr Opin Oncol. 2010 Sep;22(5):437-42.EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda.Tumwine LK, Orem J, Kerchan P, Byarugaba W, Pileri SAInfect Agent Cancer. 2010 Jun 30;5:12.HPV infection and EGFR activation/alteration in HIV-infected East African patients with conjunctival carcinoma. Yu JJ,Fu P, Pink JJ, Dawson D, Wasman J, Orem J, Mwanda WO, Zhu H, Liang X, Guo Y, Petros WP, Mitsuyasu RT, WabingaH, Remick SC. PLoS One. 2010 May 17;5(5):e10477The roles of national cancer research institutions in evolving a comprehensive cancer control program in a developingcountry: experience from Uganda. Orem J, Wabinga H. Oncology. 2009;77(5):272-80. Epub 2009 Nov 16.Endemic Burkitt lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodiumfalciparum and Epstein-Barr virus. Chene A, Donati D, Orem J, Mbidde ER, Kironde F, Wahlgren M, Bejarano MT.Semin Cancer Biol. 2009 Dec;19(6):411-20. Epub 2009 Nov 6.Mwanda WO, Orem J, Fu P, Banura C, Kakembo J, Onyango CA, Ness A, Reynolds S, Johnson JL, Subbiah V, Bako J,Wabinga H, Abdallah FK, Meyerson HJ, Whalen CC, Lederman MM, Black J, Ayers LW, Katongole-Mbidde E, RemickSC. Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin’s lymphoma in East Africa. JClin Oncol. 2009 Jul 20;27(21):3480-8. Epub 2009 May 26.Johnston C, Orem J, Okuku F, Kalinaki M, Saracino M, Katongole-Mbidde E, Sande M, Ronald A, McAdam K, Huang ML,Drolette L, Selke S, Wald A, Corey L, Casper C. Impact of HIV infection and Kaposi sarcoma on human herpesvirus-8mucosal replication and dissemination in Uganda. PLoS One. 2009;4(1):e4222. Epub 2009 Jan 20.Orem J, Maganda A, Mbidde EK, Weiderpass E Clinical characteristics and outcome of children with Burkitt lymphomain Uganda according to HIV infection. Pediatr Blood Cancer. 2008 Sep 18.Page 20Page 21

23 - 24 June 2011BURKITT SYMPOSIUM: FEATURED SPEAKERS23 - 24 June 2011BURKITT SYMPOSIUM: FEATURED SPEAKERSOrem J, Mbidde EK, Weiderpass E. Current investigations and treatment of Burkitt lymphoma in Africa. Trop Doct.2008 Jan; 38(1):7-11.Orem J, Mbidde EK, Lambert B, de Sanjose S, Weiderpass E. Burkitt lymphoma in Africa, a review of the epidemiologyand etiology. Afr Health Sci. 2007Sep; (3):166-75.Chene, A. Donati, D. Guerreiro-Cacais, A. O. Levitsky, V. Chen, Q. Falk, K. I. Orem, J. Kironde, F. Wahlgren, M. Bejarano,M. T. A molecular link between malaria and Epstein-Barr virus reactivation PLoS Pathog 2007 Jun; 3: e80.Professor C Ross Pinkerton MB., BCh., DCH, MRCI (Paediatrics), M.D.(Hons),FRCPI, FRCCH, FRAC,PDirector of Children’s Cancer Services and Staff Specialist inPaediatric Oncology, Mater and Royal Children’s Hospitals,Brisbane, Professor of Oncology, School of Medicine, Universityof Queensland, Australia24 June 201112:20 - 13:00J.Orem, Otieno MW, Remick SC. Challenges and opportunities for treatment and research of AIDS-relatedmalignancies in Africa. Curr Opin Oncol. 2006 Sep; 18(5): 479-86.Orem J, Otieno MW, Banura C, Katongole-Mbidde E, Johnson JL, Ayers L, Ghannoum M, Fu P, Feigal EG, Black J,Whalen C, Lederman M, Remick SC.Capacity building for the clinical investigation of AIDS malignancy in East Africa.Cancer Detect Prev. 2005; 29(2): 133-145.J.Orem, Otieno Mwanda W, Remick SC. AIDS-associated cancer in developing nations. Current Opinion in oncology2004,16:468-476.J. Orem, Pingfu Fu, A Ness, Otieno Mwanda W. Remick SC. Oral Combinationchemotherapy in the treatment of AIDS-Associated Hodgkin’s Disease. East Afr. Med. J. 2005; 82(Suppl) 9 2005.Ross Pinkerton is senior staff specialist in paediatric oncology at the Royal Children’s Hospital, Brisbane and Director ofthe Queensland Children’s Cancer Centre. He graduated from the Queen’s University Belfast and trained in paediatricsin Dublin and London. As Leukemia Research Fund clinical fellow at the Hospital for Sick Children Great OrmondStreet between 1982-84 he was involved in the development of treatment programmes for childhood lymphoma. In1985-86 he worked at the Centre Leon Berard, Lyon, investigating the role of high dose therapy and autologous stemcell rescue in lymphoma and the use of chemotherapy purging of reinfused marrow. He returned to the Royal MarsdenHospital , London and was appointed consultant paediatric oncologist in 1990 and was involved in the development ofthe children’s cancer service and the research facility at the Institute of Cancer Research.He was appointed Cancer Research UK professor of paediatric oncology at the Institute in 1995 and chaired the UnitedKingdom Children’s Cancer Study Group (UKCCSG) from 1999-2002. As chair of the UKCCSG NHL working group hedeveloped close links with the French paediatric oncology group leading to collaborative studies in Burkitt lymphomaand the eventual French American British FAB LMB trials.His research interests have focussed on the development of novel chemotherapy strategies and the mechanism ofdrug resistance in children’s cancers. He has played an active role in the development and execution of national andinternational clinical trials in a range of paediatric tumour types and chaired the UKCCSG New Agents group.He is the author of over 250 peer reviewed papers including a number on the management of childhood lymphoma. Heeditor of textbooks including ‘Evidence Based Paediatric Oncology’ and ‘Paediatric Oncology.’In 2003 he moved to Australia as director of cancer services at the Mater Hospital Brisbane and Professor of Oncology atthe University of Queensland and is currently clinical lead of the statewide Paediatric Haematology Oncology Network.Page 22Page 23

23 - 24 June 2011BURKITT SYMPOSIUM: FEATURED SPEAKERS23 - 24 June 2011BURKITT SYMPOSIUM: FEATURED SPEAKERSProfessor JOHN T SANDLUND, JR M.D.St. Jude Children’s Research Hospital, Memphis,Tennessee, USA24 June 201111:40 - 12:20Professor STEPHEN SCHUSTER M.D.Associate Professor Stephen SchusterUniversity Of Pennsylvania Medical School24 June 201116:00 - 16:40Dr John T. Sandlund, Jr., M.D. completed his undergraduate training at the Ohio State University. He also received hismedical degree from the Ohio State University College of Medicine and graduated a member of A.O.A. He subsequentlycompleted his pediatric internship and residency training at the Columbus Children’s Hospital in Columbus, Ohio.Dr Sandlund then received his pediatric hematology-oncology fellowship training along with an additional year oftraining as a biotechnology fellow at the National Cancer Institute, National Institutes of Health in Bethesda, Maryland.Dr Ian Magrath was his mentor at the NCI and provided key leadership in his career development which focused onthe pediatric non-Hodgkin lymphomas (NHL) - specifically Burkitt lymphoma. In 1987, Dr Sandlund was recruited tothe St Jude Children’s Research Hospital in Memphis, TN, as an assistant member with a joint appointment at theUniversity of Tennessee, College of Medicine as an assistant professor. He is currently full member at St Jude andprofessor of pediatrics at the University of Tennessee, College of Medicine. Dr Sandlund’s research at St Jude hasfocused on pediatric NHL and acute lymphoblastic leukemia (ALL). He has been the principle investigator (PI) fora number of frontline clinical trials at St Jude and more recently the PI of a phase I/II pilot study in the Children’sOncology Group, where he is also a member of the NHL steering committee. He is currently the clinical director ofthe leukemia lymphoma division and oversees NHL research initiatives at St Jude. He has authored or co-authoredover 150 publications. His current research initiatives include: Burkitt lymphoma: prospective study of biologicfeatures and late effects of therapy; lymphoblastic lymphoma: development of MDD/MRD risk based clinical trial; andanaplastic large cell lymphoma: study of targeted therapy using immunotherapeutic agents. He also participates inthe international outreach program at St Jude.Stephen J. Schuster is the Robert and Margarita Louis-Dreyfus Associate Professor of Chronic Lymphocytic Leukemiaand Lymphoma, Associate Professor of Medicine, and Associate Professor of Radiation Oncology at the University ofPennsylvania School of Medicine in Philadelphia, Pennsylvania. He also serves as Director of the Lymphoma Programand Director of Lymphoma Translational Research at the Abramson Cancer Center of the University of Pennsylvania.After graduating from Jefferson Medical College and completing a residency in Internal Medicine at PennsylvaniaHospital, Dr Schuster went on to clinical and research fellowships at the Cardeza Foundation for HaematologicResearch. In 1989, he became a member of the Cardeza Foundation and joined the faculty at Jefferson Medical College.He joined the Haematologic Malignancy Department at the University of Pennsylvania in 1998. Since that time, hisresearch has focused on the development and application of novel immunotherapies for non-Hodgkin lymphomas andchronic lymphocytic leukemia, including use of autologous tumor-derived vaccines, autologous co-stimulated T cellsfor immune reconstitution after chemotherapy, radioimmunotherapy, and monoclonal antibody therapy.Dr Schuster is a recipient of the deVilliers Society Award for outstanding support to the cause of fighting blood-relatedcancers and improving the quality of life for patients and their families, the Research Recognition Award, and the HopeAward for Medical Achievement from the Leukemia and Lymphoma Society. He has received numerous awards foroutstanding teaching and research from both Jefferson Medical College and the University of Pennsylvania.Dr TRISH SCANLAN M.D.The Ocean Road Cancer Institute,Tanzania23 June 201113:00 - 13:25Dr Trish Scanlan is a graduate of University College Dublin and spent most of her Irish career at Our Lady’s Children’sHospital Crumlin in Dublin. In 2007 she relocated to Dar es Salaam in Tanzania as the INCTR East Africa ProgrammeCo-ordinator and to run the National Children’s Oncology Centre in the Ocean Road Cancer Institute. The service hasrecently relocated to the University Hospital. She is still in Tanzania and admits, she is still mostly sane!Page 24Page 25

23 - 24 June 2011BURKITT SYMPOSIUM: FEATURED SPEAKERS23 - 24 June 2011BURKITT SYMPOSIUM: FEATURED SPEAKERSProfessor OWEN PATRICK SMITH MA, MB, BA Mod.(Biochem.), FRCPCH,FRCPI, FFpathRCPI, FRCPEdin, FRCPLon, FRCP Glasg, FRCPath, DHMSA, Hon FTCDProfessor of Haematology,The University of Dublin, Trinity College Dublin, IrelandConsultant Paediatric Haematologist,Our Lady’s Children’s Hospital, Crumlin, Dublin 1223 June 201109:30 - 10:0010:00 - 10:2010:00 - 12:0513:00 - 14:5024 June 201117:10 - 17:5017:50 - 18:05Professor Smith is a Consultant Paediatric Haematologist at Our Lady’s Children’s Hospital Dublin, and is Professor ofHaematology at the University of Dublin, Trinity College Dublin. His active research areas of interest include: childhoodand adolescent leukaemias & lymphomas, bone marrow failure syndromes, angiogenesis and haematologicalmalignancies, the molecular and cellular basis of the inflammatory - coagulation interface in human disease. Theco-author of more than 300 research original articles, letters, books, book chapters and papers, Professor Smith isa Fellow of the Royal College of Pathologists, the Royal College of Physicians of Dublin, London, Glasgow, Edinburghand the Royal College of Paediatrics and Child Health. He is a member of numerous associations and societies,including; the Medical Research Council Childhood Leukaemia Working Party, the International Berlin FrankfurtMunster Study Group for Childhood Leukaemia, the United Kingdom Haemophilia Centre Directors’ Organisation,the European Paediatric Network for Haemophilia Management, the United Kingdom Children’s Cancer Group, thePaediatric Haematology Forum of the British Society of Haematology, and the European Paediatric Network forSevere Congenital Neutropenia. He was awarded the Graves Medal by the Royal Academy of Medicine and HealthResearch Board in 2001 for his research into the pathobiology and novel therapeutic strategies in severe sepsis thathad received international acclaim. In 2006, Professor Smith was awarded the St Luke’s Medal by the Royal Academyof Medicine and St Luke’s Hospital for his work on improving outcomes in adolescent cancers with specific referenceto the haematological malignancies. He was admitted to Honorary Fellowship of Trinity College Dublin (the oldest andmost valued tradition of the University) in 2009.Professor LOUIS M STAUDT M.D. Ph.D.Chief, Lymphoid Malignancies Section, Deputy Chief,Metabolism Branch, Centre for Cancer Research,National Cancer Institute, Maryland, USA24 June 201110:20 - 11:00Dr Staudt received his B.A. from Harvard College in 1976, graduating Cum Laude in Biochemistry. He was awarded aMedical Scientist Training Program fellowship at the University of Pennsylvania School of Medicine and received his M.D.and Ph.D. degrees in 1982. His Ph.D. thesis in the field of immunology, performed in the laboratory of Walter Gerhard,revealed somatic hypermutation as a mechanism of rapid antibody diversification during normal immune responses.Following Internal Medicine training, he joined Nobel Laureate David Baltimore’s laboratory at the Whitehead Instituteas a Jane Coffin Childs Fellow. There he cloned and characterized the first tissue specific transcription factor, Oct-2.He established his laboratory in the Metabolism Branch, National Cancer Institute, in 1988, and currently studies themolecular basis of human lymphoid malignancies. Dr Staudt is currently Deputy Chief of the Metabolism Branch andhe also co-directs the Lymphoma/Leukemia Molecular Profiling Project (LLMPP), a multi-institutional consortiumthat aims to develop a new molecular framework for the diagnosis of all lymphoid malignancies. Dr Staudt serveson the Editorial Boards of Cancer Cell, The Journal of Experimental Medicine and Genome Biology. He has receivednumerous awards for his research, including the 2009 Dameshek Prize from the American Society of Hematology foroutstanding contribution in hematology.Dr Staudt’s laboratory initiated the use of genomic-scale gene expression profiling to define the molecular basis oftherapeutic response and survival in lymphoid malignancies. This effort revealed that the most common type of non-Hodgkin’s lymphoma, diffuse large B-cell lymphoma, is actually comprised of three distinct diseases with differentresponses to chemotherapy. With respect to Burkitt lymphoma, Dr Staudt’s laboratory created a gene expressionbaseddiagnostic method that distinguished this entity from diffuse large B cell lymphoma (Dave et al. NEJM 2006354:2431). This molecular diagnosis was based on 4 gene expression signatures, with Burkitt lymphomas havinghigh expression of c-Myc and its target genes, and a subset of germinal center B cell-restricted genes, and lowexpression of NF-kB target genes and MHC class-I genes. Importantly, Dr Staudt’s gene expression-based diagnosticmethod identified a substantial number of cases as ‘molecular’ Burkitt lymphoma that appear to be misdiagnosed asdiffuse large B cell lymphoma by current diagnostic methods. This distinction is critically important because Burkittlymphoma and diffuse large B cell lymphoma require different chemotherapeutic regimens to be cured.Page 26Page 27

23 - 24 June 2011BURKITT SYMPOSIUM: FEATURED SPEAKERS23 - 24 June 2011BURKITT SYMPOSIUM: FEATURED SPEAKERSProfessor DENNIS HOWARD WRIGHTFormer Histopathologist at Makerere Medical School, Uganda23 June 201110:20 - 10:45Professor JOHN L. ZIEGLER M.D., M.Sc.Professor at University of California-San Francisco,San Francisco, California, USA23 June 201111:10 - 11:4524 June 201117:10 - 17:50I was educated at the City of Norwich boys grammar school before going to the University of Bristol to study Medicine.I was awarded an intercalated BSc in Physiology in 1953 and qualified MB, ChB (Hons) in 1956. After internshipsin paediatrics and surgery I trained in Clinical Pathology at Bristol Royal Infirmary. In 1960 the Recruitment Boardallowed me to take up the post of Lecturer in Pathology at Makerere College, Uganda, instead of doing two yearsnational service. Soon after my arrival in Uganda Dr Greg O’Conor, who collaborated with Denis Burkitt on two earlypublications, left Uganda and I took over as “Mr Burkitt’s pathologist”. He called me to theatre when he operated onlymphoma cases so that I could collect fresh tissue, blood and bone marrow. In return I was able to give him a rapidcytological diagnosis and on many occasions administer the first dose of cyclophosphamide while I had a needle ina vein for blood taking. Denis and I collaborated together on a number of published studies on Burkitt lymphoma.Together, we edited a book on Burkitt lymphoma in 1970. We travelled together to a number of meetings in Europeand America. At a Symposium on lymphoreticular tumours in Africa held in Paris in 1963 I proposed that the tumour,then often given the unsatisfactory name “African lymphoma” or “childhood lymphoma” should be called Burkittlymphoma. (This was accepted except that some of the big guns insisted that we use the term Burkitt’s tumour sincethey were not sure that it was a lymphoma).I was awarded an MD for my thesis ‘Malignant lymphomas in Uganda’ in 1965. Denis left Uganda in 1966 and I followedin 1968 to take up the post of Senior Lecturer and later Reader in Pathology at the University of Birmingham. In 1971 Iwas appointed Professor of Pathology at the newly formed Medical School at the University of Southampton.John L. Ziegler, M.D., M.Sc. was educated at Amherst College where he received a bachelors degree in EnglishLiterature in 1960. After earning an M.D. at Cornell University Medical College he undertook medical residency trainingat Bellevue Hospital and Memorial-Sloan-Kettering Hospitals in New York City. Joining the National Cancer Institute in1966, he embarked on a long career in cancer research. He was the founding Director of the Uganda Cancer Institutein 1967 and after five years of research, teaching and clinical work in Uganda he was honored by the Albert and MaryLasker Award in 1972 for improving the cure rate of Burkitt lymphoma, a common childhood malignancy. During the1970s he was Chief of Pediatric Oncology and later Director of Clinical Oncology at the National Cancer Institute.In 1981 Dr Ziegler joined the University of California San Francisco as Professor of Medicine in residence and Chief ofStaff for Education at the VA Hospital. Here, he participated in the early research on the AIDS epidemic, being the firstto show an association with malignant lymphoma and Kaposi’s sarcoma — tumors he encountered earlier in Uganda.Ziegler was also instrumental in the discovery of viral causes of Burkitt lymphoma and Kaposi’s sarcoma.In 1985 Prof Ziegler became the Founding Director of the UCSF AIDS Clinical Research Center and made manyscientific contributions in the area of HIV-associated malignancies, both in the USA and in Uganda. He was invited toconsult with the World Health Organization in 1994-96 and in 1997 earned a masters degree in epidemiology at theLondon School of Hygiene and Tropical Medicine.From 1998 to 2007, Ziegler has directed the Cancer Risk Program at the UCSF Comprehensive Cancer Center, now oneof the leading genetic counseling and testing centers for hereditary cancer in northern California. Starting in 2007, hewas named Director of the Global Health Sciences Graduate Program, crafting a curriculum for a masters degree inglobal health sciences at UCSF. This Program, the first of its kind in the US, graduated an inaugural class of 7 studentsin 2009 and enrolment has quickly reached 30 students annually. Ziegler has authored over 240 scientific articles,chapters and reviews and is the recipient of numerous awards that honor his work in cancer and global health.Ziegler has had a career-long interest in medical education and, as a recipient of two Fulbright awards, has taughtclinical medicine for eight years at Makerere University in Kampala, Uganda. He has also taught as visiting professorat Cambridge and Oxford Universities, Cairo University, and at the London School of Hygiene and Tropical Medicine.Page 28Page 29

23 - 24 June 2011BURKITT SYMPOSIUM: NOTES23 - 24 June 2011BURKITT SYMPOSIUM: NOTESNOTESNOTESPage 30Page 31

23 - 24 June 2011BURKITT SYMPOSIUM: NOTESNOTESPage 32